Episode 240: The Future of Stem Cell Medicine: Part 2
With Dr. Avhie Herskowitz
Ashley:
Hello, everyone. Welcome to Cellular Healing TV. I’m Ashley Smith. In this special episode, Dr. Pompa brings us on site to visit Dr. Ahvie Herskowitz at his stem cell center in San Francisco. You may remember Dr. Ahvie from Episode 227 where he shared so much about the revolutionary advancements in stem cell medicine. This time we’ll see firsthand the procedures that are being as used as stem cell treatments are becoming more customer driven and reemerging as a viable way to transform lives. Stem cells are for all of us who want to age gracefully, and these new impressive methods of optimization will ensure that we don’t just live longer but that we live longer healthfully. Following the interview, we’ll see two quick demos of the discussed stem cell treatments that Dr. Ahvie performs on Dr. Pompa, so stay tuned for those. In case you missed the last episode with Dr. Herskowitz, he is the founder of Anatara Medicine based in San Francisco, a world-class integrative medical center. He is also the founder of the San Francisco Stem Cell Treatment Center. With his 37 years of experience, Dr. Herskowitz is one of the most renowned antiaging specialists in the US and health practitioners.
Dr. Pompa’s Live It to Lead It Conference is coming up on November 2 in Los Vegas. We’d love to have you join us, and at the end of this episode, stay tuned for a special code for you to take $200 off your ticket. We are so thankful that Dr. Herskowitz is welcoming us in his practice today, so let’s jump in. This is Cellular Healing TV.
Dr. Pompa:
Dr. Ahvie, I traveled all the way from Park City, Utah to come here to San Francisco because you’re doing some unique things. This is, by the way, Part 2. If you watch Episode 227, you’ll see me introduce you. I give more of a background in your story in that one, so make sure you watch that episode of Cell TV. I came here because I had to see it for myself, honestly. I’m that guy, right?
Dr. Herskowitz:
Yes.
Dr. Pompa:
I like to see it. I like to experience it. If it’s real and it’s working and it’s better, I bring it to them, so that’s why I’m here.
Dr. Herskowitz:
Thank you.
Dr. Pompa:
Thanks for having me.
Dr. Herskowitz:
You’re welcome.
Dr. Pompa:
It was an awesome day, so I got to experience everything. Matter of fact, you’ll get to see video, actual video of these things that we’re talking about so exciting episode.
Dr. Herskowitz:
It was a long day.
Dr. Pompa:
It was, yeah. Probably longer for you because I was sitting back relaxing most of the time. I am; I’m impressed with your methods, and I have to admit, I mean, I do a lot of reading on this topic. Things that I heard you do in our first interview, I was like, okay, he’s doing some of these new things that I read about, so let’s talk about it. Stem cells, I don’t know. People ask what is the percentage that works versus that doesn’t work, right? It doesn’t work for everything. I don’t think anything works for everybody.
Dr. Herskowitz:
No, that’s correct. Nothing does, of course. I think, generally speaking, the numbers for all comers, for all indications, probably roughly around 70-some odd percent.
Dr. Pompa:
Okay, all right, so my question then is, okay, how do we up that percentage, and why doesn’t it work for some people? Let me ask that question first.
Dr. Herskowitz:
It depends on the host as well, not just the stem cells. It just depends on what environment the stem cells are going into. It’s the number. It’s the quality, and then, on top of that, it’s…
Dr. Pompa:
The number of the stem cells, the quality of the stem cells.
Dr. Herskowitz:
That’s right, and then it’s also the optimization and, as I say, activation and localization. I mean, you have to have everything optimized and ready to go in order to get the full benefits. The stem cells know what they’re supposed to be doing. It depends on whether the environment is going to support them or not and for how long.
Dr. Pompa:
I mean, one of the things you and I talked about is oxidation and inflammation is the death of new stem cells. I’ll back up, all stem cells, right? Yeah, so if you’re that person, sick, toxic, challenged, probably the people who need stem cells the most. There can be some challenges, even if you have a donor, meaning umbilical cord, which we did today. We’re going to talk about that. Whatever it is, even though those are good stem cells, you’re putting them in an environment that can really keep them from being utilized, if you will, or you’re the sick person, and you take your own stem cells. They may not be viable, meaning that effective, correct?
Dr. Herskowitz:
That’s correct.
Dr. Pompa:
All right, so the procedures that you do here can change those odds.
Dr. Herskowitz:
That’s correct. That’s the art in terms of—I mean, giving stem cells or purchasing them from a vendor and giving them to a patient is not an art form, but optimizing them and getting the patient prepared for them and making sure that the environment can support their activation and their proliferation over the next six months is the art form.
Dr. Pompa:
All right, so we’re going to talk about that procedure and how to maximize stem cells. This may be the first time someone’s watching this. I do feel like, for them, we need to back up, and those of you who know about stem cells, this will still be a good review. All right, let’s just give them a general idea. First of all, I had a conversation at dinner last night, very intelligent man. He’s looking at me with the stem cell thing, and then I could tell that—I couldn’t wait to hear the next question out of his mouth. He said, yeah, but isn’t there a lot of controversy about stem cells? I think some people watching this, isn’t their controversy? Is this even legal? I mean, talk about that.
Dr. Herskowitz:
When we first started using stem cells in the United States, they were called autologous stem cells or stem cells that were derived from the patient’s own tissue. The majority of those cases, the overwhelming majority were either from bone marrow, or adipose cells, or fat cells derived so adipose derived or bone marrow derived, but they’re coming from the patient’s own body. Each one, each sample is completely unique, and each sample from any given person is completely unique from the sample the next day or the next week, so that particular body fluid or body tissue is not typically governed by the FDA. At this point, the FDA has no definitive position on stem cells in the United States.
Dr. Pompa:
Okay, so let’s back up even further, though. I think, when people say is this even legal, they’re thinking of back to Christopher Reeve’s days, right?
Dr. Herskowitz:
Right.
Dr. Pompa:
Where it was like, oh, my gosh, stem cells was outlawed. No, you can’t do it. I mean, there was so much controversy because people were thinking aborted babies. Things have changed since then.
Dr. Herskowitz:
Yeah, they’re completely different, so that’s where the controversy lies. After we had the basic signs that suggested that this will be a major revolution in medicine, we had the political system come in and squash the innovation for some 10, 20 years, so now it’s emerging again with studies that are considered to be clinical research studies. The controversy is is that they’re patient funded. They’re not all NIH funded studies, which are typically done for commercial purposes. Here’s the private sector being pushed by the patients in order to get access to their own body materials in this case, so it’s considered to be a revolution that’s happening that consumer driven and not only commercially driven.
Dr. Pompa:
Yeah, I mean, I feel this amazing technology is out there. I feel like people don’t even know it’s an option, and that’s why I love doing these shows. It transformed my life, and I see so many lives transformed from it. All right, another myth I think they would be thinking is, okay, I’m going to get DNA from somebody else, and I could develop a disease. How likely is that?
Dr. Herskowitz:
It’s very unlikely, number one. That cannot happen when you receive your own autologous stem cells, number one. Number two is that experience comes from the older literature where patients who received the earliest forms of embryonic cells with high levels of the donors self-antigens on the surface. In those days, they weren’t selected out. In those cases, they were rare examples, still rare, but examples of patients developing benign tumors, usually years later. Afterwards and this is about 30 years ago, we haven’t seen the development of malignancies in any case, but the confounder here was that some patients did develop benign tumors. It’s not the case any longer.
Dr. Pompa:
Yeah, right. We still hear that, and that drives that philosophy. All right, who’s it for? Who is this for?
Dr. Herskowitz:
I think stem cells are for all of us that want to age gracefully
Dr. Pompa:
That’s why I’m here, yeah. Honestly, I mean, no doubt it transformed my disc. I mean, there’s some things that it did for me absolutely in physical, but you and I, no doubt, are saying, hey, I don’t want to just live longer. I want to live longer healthy. I think this is an advantage we have that we’ve never had.
Dr. Herskowitz:
Yes, we never had that before. I agree. When you and I have discussed this offline, we say that the—those of us that want to live gracefully, there are two weak areas that we have, two larger weak areas without even having any specific illnesses. That’s our musculoskeletal system, and I believe our brain. As you’re the expert in in terms of detoxification, you know that the brain is filled—is one big lipid source.
Dr. Pompa:
Yeah, holds the toxins.
Dr. Herskowitz:
It holds the toxins in, so I would be most concerned with the brain and musculoskeletal system. In this case, in the United States, roughly two-thirds of all cases of patients using their own cells and now these umbilical sourced embryonic cells…
Dr. Pompa:
Which I got today.
Dr. Herskowitz:
Are using it for joint purposes. Then they’re saying, well, listen, I developed a joint problem typically from inflammation. I want to deal with the inflammation outside of my joint, and then they have to get the stem cells intravenously…
Dr. Pompa:
Which I did.
Dr. Herskowitz:
To have a systemic effect.
Dr. Pompa:
Yeah, I did. I did that today. You’re going to see that video because you actually explain that in the video, so I won’t have you explain it more. We’ll have that right here. Yeah, I mean, that is—I think that it is my goal. I mean, I want to not just live long. Forget about it. I want to be able to do the things I love to do long.
You’re right; it’s the joints, right? I mean, my knees, I started to feel my knees, just sports, many things through the years. I think we start losing viable stem cells, and for you watching, that’s how you heal, right? I mean, if we cut our arm, you don’t grow eyeballs on your arm. Your body sends stem cells there, and it makes new tissue. The older we get, unfortunately, the longer that takes, whether it’s your skin, whether it’s your knee. Is that another reason to do, say, just an IV of some of these young stem cells from umbilical cord?
Dr. Herskowitz:
That’s the strategy for prevention. We can prevent, or you could say, listen, I have a little signal coming from one location. I have a little signal coming from a bit of a cognitive issue. I forget where my keys are. I’m an executive, or I have a high-powered position. I have a stressful position, and I’m beginning to slow down relative to the 30 plus year olds that are taking over. Then that’s when you go ahead, and you do it preventively.
Dr. Pompa:
Yeah, that’s exactly right. I think that, most people watching this, they don’t realize that their viable stem cells are dropping. They don’t realize that they’re more in a state of inflammation, and we have this technology that can really, I mean, turn back the clock. I mean, that’s the cool thing. No doubt, chronic pain, they’re doing it for neurodegenerative conditions, Parkinson’s, MS, cancer, I mean, all of it. All right, let’s look at your procedure. We said that there is this 30% that may not respond. You’re upping those odds. Talk about what this clinic does different that I experienced today.
Dr. Herskowitz:
It’s obvious that you want to be able to optimize the terrain, so to speak, in terms of what the environment is. Right now, you could—if you dis-inflamed the body, if you lower the inflammatory signals right away, right before you get the procedure, and you could buffer the inflammation that’s in everyone’s system today, then the stem cells will have an easier time of it. To locate those sources that are signaling from a position of some chronicity rather than some baseline study, baseline effect. We have our way of doing that, and we do that intravenously typically because that’s the strongest way to do it.
Dr. Pompa:
Mm-hmm, get that immediate effect.
Dr. Herskowitz:
In the first video that we did a few months ago, you mentioned that you optimized your last procedure by intermittently fasting.
Dr. Pompa:
Yeah, I fasted, yeah.
Dr. Herskowitz:
Yes, that also has an anti-inflammatory component to it as well as…
Dr. Pompa:
I’m writing a book on that right now which will be released on how to prepare even a month ahead, right? I mean, I have a seven-week program, literally, that goes up to it. Here we are.
Dr. Herskowitz:
Here we are, yeah, so the day. We put in an intravenous catheter, and then we gave you intravenous ozone and intravenous glutathione, which, again, immediately before accepting a stem cell treatment we’ve learned over the last four years here at our clinic that you can get higher yields when you’re using your own stem cells.
Dr. Pompa:
Right, so when you’re extracting them from bone or fat, you’ll get a higher yield, literally measurable when you do these procedures. That’s important.
Dr. Herskowitz:
Yeah, so you get higher yield. Now, we are extrapolating that you’re not getting a higher yield when you’re taking a set amount of embryonic cells because that set amount is dictated by the vial and the size of that vial. We’re extrapolating that you’ll make them more effective.
Dr. Pompa:
Yeah, getting a higher usage uptake.
Dr. Herskowitz:
Yes.
Dr. Pompa:
Okay, so let’s talk about it. We did that. We did the ozone.
Dr. Herskowitz:
Yes.
Dr. Pompa:
Why would ozone make a difference?
Dr. Herskowitz:
Eventually, it induces your antioxidant system in a major way. It has a global set of effects that protect the microenvironment, detect the microcirculation, anti-inflammatory. They’re anti-infective. It’s not an issue for most patients, but it does have that quality.
Dr. Pompa:
Infections raise oxidation, which is a problem, so it would knock it down.
Dr. Herskowitz:
Right, it knocks it down. It also allows the penetration of the stem cells to go deeper and deeper down into the system.
Dr. Pompa:
All right, then you mentioned glutathione. Glutathione’s a major antioxidant.
Dr. Herskowitz:
Yes.
Dr. Pompa:
You didn’t just do glutathione. By the way, every cell produces it, but many people have low glutathione, which that’s a problem. That could upregulate oxidative stress and inflammation. You did glutathione followed by a special phosphatidylcholine called Essentiale from Germany, I believe, and I’ve done a lot of it in my past. It’s amazing for the cell membrane, so you did the glutathione followed by that. That’s unique.
Dr. Herskowitz:
Yes.
Dr. Pompa:
Now I’m going back in my mind. Okay, so then what did we do? Then we did the IV.
Dr. Herskowitz:
That’s right.
Dr. Pompa:
We did the IV of—I mean, you always make the point of what are they counting? It was millions, 90million stem cells.
Dr. Herskowitz:
Yes, I think you got 90 million cells. I told you that, if you wanted to get the full effect, and I felt that the therapeutic effect using this particular source was one to one and a half million cells per kilogram.
Dr. Pompa:
Per kilogram, yeah.
Dr. Herskowitz:
You weighed roughly 70 kilos, so we gave you a little bit more than 1.4 or something like that.
Dr. Pompa:
Merilee got 2 vials, which would be about 60 million because of her weight.
Dr. Herskowitz:
Yes, that’s right. You got that through an IV drip of running over about a half an hour.
Dr. Pompa:
Yeah, we explain in the video that we’re going to add in here why that’s really important. Okay, so then we did some injections in some of my hot spots after that. I actually found you had an amazing approach. I felt zero. I’ve gotten a lot of injections in my day, right? Either you’re out cold and you don’t feel it, or you use this icing method. You hit it with…
Dr. Herskowitz:
Yeah, the icing method.
Dr. Pompa:
Yeah, you hit with some…
Dr. Herskowitz:
Ethyl chloride.
Dr. Pompa:
Ethyl chloride, is that what is?
Dr. Herskowitz:
Yes.
Dr. Pompa:
Okay, I felt nothing. Merilee, she’s really tough, but when it comes to this, she’s a wimp. She felt nothing. Anyways, yeah, I mean, felt it, the pressure going in, which I actually like that feeling. You girls thought I was crazy, but I’m not crazy. I’m telling you, I like that. Okay, so then after the stem cells were injected, then you did something else that’s unique. You have a special laser, which you’re going to see in the video. It looks…
Dr. Herskowitz:
Like an octopus.
Dr. Pompa:
It looks really expensive. I thought maybe it was probably the price of a car, but yeah, it looks like an octopus. Anyway, so tell us about the laser. Why would that be more effective in helping with these yields? Not yields, I’m sorry, the effectiveness of the stem cell.
Dr. Herskowitz:
Yeah, so as I said before, what we’re looking for is to be able to activate and localize. Now, when you look at the literature about things that activate the stem cells in vitro, in the test tube, you realize that it’s clear that photonic energy or light energy does, and so the laser is an obvious source of being able to activate them. In this case, we’re already localizing them because we’ve injected it in your C-spine ad your lumbar spine and your right knee, but it’s already been localized. I want them to activate there locally and stay there as long as possible, and understand that they have to communicate with the local environment as much as possible right away. That’s perhaps why you felt an immediate effect. Now, you don’t feel an immediate effect…
Dr. Pompa:
A massive immediate effect, yeah.
Dr. Herskowitz:
You don’t feel an immediate effect because you’ve grown new cells. You feel the immediate effect because they make the tissue more efficient. In this case, you were able to increase your range of motion because you were able to—ionic transport across the cell membranes was more effective, so you were able to relax more. Then it lowers the inflammatory burden as well immediately, but the point is is that we try to activate them and make them stickier so that they can communicate with the environment better. That’s the way we do it. I think there’s also pulsed ultrasound that you can use. We don’t use it, but it can be used as well to activate these cells.
Dr. Pompa:
Yeah, I mean, the cells are attracted and respond to energy, if you will, whether it’s light, whether it’s sound, whatever it is. Yeah, no, I mean, I was impressed with that. All right, last topic that I think is a really important one. Something that you’re doing here that’s very unique is—I’ve been reading about the VSELs, very small stem cells, and matter of fact, they’re able to cross the blood-brain barrier. You’re doing that here. This could be the future. We talked about exosomes, which is another thing that you do, which I believe is part of the future. That’s not a cell. That’s just a communication molecule, if you will. What are these VSELs that you’re doing?
Dr. Herskowitz:
VSELs are rarer forms of stem cells. They’re full cells that have nuclei. They have surface characteristics that can be labeled by immunohistochemistry, but they’re not common. They’re just not floating around in great numbers. They originally identified I believe in bone marrow, but they have no bone marrow cell surface markers. They’re not bone marrow derived, so they can be found—then they were found more in tissues and various organs. They’re organ based, and their jobs are to perhaps act as the more primitive forms of stem cells, the so-called pluripotential stem cells.
Dr. Pompa:
Meaning they could become any cell. That’s what the means.
Dr. Herskowitz:
Yeah, so when we have the fertilization, right, before we hit 32 cell counts, those cells are called totipotential. That ultimately becomes the whole human, right? Pluripotential has the capability of becoming any given organ in the three germ layers, right? That’s ectoderm, mesoderm, and endoderm, right? These are perhaps more primitive than the adult form or even the embryonic form. The question is how do they do it, number one, and then how do we find them and activate them to a similar extent that they’ll make a big clinical difference? Philosophically, they’re smaller than entire stem cells, either embryonic or your own, so that they—if you wanted a solution for a neurodegenerative issue, then you’d go with these types of cells by principle because they can more easily cross over the blood-brain barrier.
Dr. Pompa:
Yeah, that was one of my questions too is where do you see the future of these cells being used versus the other cells? By the way, the ones that you would get from your bone, or fat, or even cord, embryonic cord, those are multipotent. Meaning that, okay, they can become a lot of things, but these are pluripotent, meaning they can become just about anything. Just to differentiate what we’re talking about here. Where else would you say that you see the future of these VSELs?
Dr. Herskowitz:
I believe that the one most obvious advantage is they’ll cross over.
Dr. Pompa:
Right, the brain, in the blood-brain.
Dr. Herskowitz:
Through the brain. I think they also may have specific unique characteristics for ophthalmic indications going forward, but I think they’ll be more likely than the other cell types to actually become regenerative tissue. For us, if we have patients who need to regenerate liver and kidney and heart and so on, they may be more effective and more efficient at it. Now, stem cells, we know one of the major effects is the way they talk to the community. When the stem cells are injected into either IV or into your joint, they have to communicate, and that’s what we call the paracrine effect. They do that with types of informational packets. The informational packets are called amongst other things exosomes. There’s a whole new vocabulary out there.
Dr. Pompa:
Yeah, we’ve talked a lot about exosomes.
Dr. Herskowitz:
Exosomes, extra cellular vesicles, there’s a dozen or so terms that are being used over the last ten years because they’re important communications networks. They contain RNA. They contain proteins. They contain proteins from the sources of where they come from. They’re going to be many, many different forms of it, but the VSELs, the very small stem cells perhaps also have different forms of RNA that are more primitive and have more capability of becoming what the environment truly is requiring.
Dr. Pompa:
Needing, yeah.
Dr. Herskowitz:
Yeah.
Dr. Pompa:
Yeah, I mean, you could imagine this is the future of many different conditions, these things. I think we’ve had conversations too where it’s like this is the future of medicine. We’re learning more and more how to put these things together and really make an impact. I think the thing that I want them to hear is this is here now. This is here now. Give them your information how they can find you. You have people flying in from all over to come here in San Francisco, moments from the airport, so tell them how to find you.
Dr. Herskowitz:
The stem cell center is called the San Francisco Stem Cell Treatment Center. I think the website is sfstemcellcenter.com. We also have an integrative medicine unit surrounding the stem cells because we want to optimize patients. We want to not just give you an injection, and you go home. We’d like to optimize you over the course of your stay and also the course of the next six months. That’s called Anatara Medicine, A-N-A-T-A-R-A-medicine.com, but San Francisco Stem Cell Treatment Center and you’ll find us.
Dr. Pompa:
Yeah, take advantage of it. Thanks. I appreciate. I appreciate the day, and I appreciate everything you’re doing and a lot of new research.
Dr. Herskowitz:
Thank you very much. Bye-bye.
Dr. Pompa:
Yeah, absolutely. Okay, Ahvie, what are we doing here?
Dr. Herskowitz:
Today, we are going to give you embryonic umbilical cord cells both locally as well as a boost intravenously, which is what you’re getting right now.
Dr. Pompa:
It came in these little vials. How many cells approximately are in these vials?
Dr. Herskowitz:
With this formulation that we use, these are high concentration vials that have 30 million cells in them. I feel that it’s important to optimize patients before you give them stem cell therapies, and you can do that both on the day of the treatment, as well as for the three to six months afterwards. For you, someone who’s generally optimized quite intelligently…
Dr. Pompa:
I like that.
Dr. Herskowitz:
Very intelligently, we gave you intravenous ozone therapy and glutathione therapy, which is a basic formula. There is an art to it in terms of the long-term optimization strategies to speak to stem cells and optimize their function over time, so they’re not diverted. Ozone is immunomodulatory. It’s anti-infective. We’re not using it for this reason today, but it does initiate repair mechanisms and so on. It allows the microcirculation to be a bit more toned so that you’ll get the full benefit. Now, we’re doing this before we do the injections. That’s my own bias. I think that’s your bias as well.
Dr. Pompa:
I do. I think it’s great. Yeah, I think it makes a lot of sense.
Dr. Herskowitz:
Yeah, the stems cells enter locally into a more pristine environment, so that’s what we’re doing right now.
Dr. Pompa:
I mean, oxidation inflammation is the curse of stem cells, period, I mean, especially new stem cells, so this would make sense. It would downregulate some of that.
Dr. Herskowitz:
Yes, it will. We’ll run this around 30 minutes or so. Then move to the other space, and do the local injections.
Dr. Pompa:
Now, I have to ask the question. I mean, do some of these make their way to places that potentially would need stem cells?
Dr. Herskowitz:
That’s the idea of them, yeah. Most of the early effect will be, again, both anti-inflammatory and increasing mitochondrial function, so it’ll be more efficiency and then optimization. Then afterwards, over a three to four month period, you’ll get regenerative strength with the stem cells.
Dr. Pompa:
You’re doing great work here, so appreciate that, Dr. Ahvie Herskowitz.
Dr. Herskowitz:
Yes, that’s a tongue twister.
Dr. Pompa:
John Hopkins guy but, anyways, right here in San Francisco, thanks.
Dr. Herskowitz:
Thank you.
Dr. Pompa:
Ahvie, this is one of the things you do unique is that you use lasers post stem cells, so I want you to tell them why.
Dr. Herskowitz:
I think that the literature that we looked for was ideas to localize and activate. Localizing stem cells to a given region, be it now you can inject them locally as we’ve just injected L4, L5, and S1 in your back with embryonic cells, with the umbilical cells, so they’re ready to localize. We want them to be activated a little bit more in a more pronounced way than if they weren’t exposed. The ways to do that—one of the chief ways to do it is with laser or photonic energy. Here we have infrared laser, six of them, two of them on either side of L4, L5, and S1, and they will activate them. What happens when they activate is that they’ll develop adhesive qualities so that they’ll become more adherent to the tissues, so they’ll stick a little bit longer. When they stick a little bit longer, you can imagine that they then transfer their exosomes, and they transfer their paracrine effects more efficiently. Then when they stick, they’ll be there a little bit longer than usual, and so the paracrine effect will be more pronounced for a longer period of time.
Dr. Pompa:
Explain to them what that means, the paracrine effect.
Dr. Herskowitz:
That means that you injected the cells now locally, so they’re in your ligaments, for example, that you have asked to have more strengthened and close to the facet joint. You don’t have arthritis, but the ligaments insert there. You want them to be—you want the messengers of how they communicate with the environment to be more efficient. The way that happens is the stem cells communicate but don’t necessarily become the new cells. Their ligament cells don’t—they don’t become new ligament cells, but they tell your ligament cells to become more robust and filled with the appropriate proteins properly.
Dr. Pompa
Yeah, so it stimulates the body’s healing, really, in a sense.
Dr. Herskowitz:
Mm-hmm, so that’s what it does. The paracrine effect is at least one of the major effects if not the major effect.
Dr. Pompa:
Then can this be done other places in the body or even things that aren’t pain necessarily, holding the cells into those areas?
Dr. Herskowitz:
Yeah, so this can be done on the skin. It could be done into a joint space. It can be into a soft tissue space as well, so you can keep the cells there longer. They’re also stickier, but they’re activated.
Dr. Pompa:
Okay, thanks, Dr. Ahvie.
Dr. Herskowitz:
We’ll run these for 20 minutes, and your back, we’ll run 20 minutes and your upper C-spine. Then, if we have a chance, we’ll run it on your right knee.
Dr. Pompa:
Yeah, perfect. Thanks, doc.
Dr. Herskowitz:
Thanks.
Ashley:
That’s it for this week. We hope you enjoyed today’s episode. Practitioners, you are invited to join us at Dr. Pompa’s seminar in Los Vegas from November 2 to the 4th. Go to hcfevents.com for more information, and you can use the promo code CHTV to take $200 off the ticket price. We’d love to see you there. We’ll be back next week and every Friday at 10 a.m. Eastern. You may also subscribe to us on iTunes or find us at podcast.drpompa.com. Thanks for listening.
